Osimertinib (Osimert 80 mg) is a medication used in the treatment of non-small cell lung cancer (NSCLC), specifically for patients with tumors that have specific mutations in the epidermal growth factor receptor (EGFR) gene. It is an oral, third-generation EGFR tyrosine kinase inhibitor.